ArtiVeda contains the Ayurveda Dvipaantara Damanaka, 500mg of Artemisia Powder.
It will be available in India at the end of December to treat Covid-19.
The main ingredient in ArtiVeda is Artemisinin which is derived from the plant species Artemisia and has been used medicinally to treat fevers, headache and inflammation for centuries in India and China.
We discovered that Artemisinin is highly potent at inhibiting the ability of the COVID-19 causing virus (SARS-CoV-2) to multiply while also having an excellent safety index. Our results indicate that Artemisinin has an EC50 of 0.45 ug/ml and Safety Index of 140.
As a TGF-β inhibitor ArtiVeda should target multiple viral threats including Covid-19 by suppressing both viral replication and clinical symptoms that arise from viral infection. With treatment, viral replication is suppressed, IFNβ is induced and innate and adaptive immune responses are suppressed. The end result is protection from both viral and immune driven pathologies (ARDS and cytokine storm).
Oncotelic is working with distributors in low and middle income countries to provide a clean supply to help manage this humanitarian crisis.
A similar product, ArtiShield will be marketed outside of India.